Breaks Categories: News

ThursdayJun 18, 2020 12:22 pm

BioMedNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) TumorGenesis Secures First Commercial Sale of its Unique Ovarian Cancer Cell Media

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its TumorGenesis division sold its first order of its unique ovarian cancer cell culture media for cancer cells collected from patient derived samples (“PDx”) through its distributor US Biological Corporation. According to the update, the media used to grow the novel and unique ovarian cancer cell lines, licensed by TumorGenesis and its partner, GLG Pharma, are able to retain 95%+ of the DNA and RNA as well as crucial proteomic signatures. “Capturing and culturing and then being able…

Continue Reading

TuesdayJun 16, 2020 12:45 pm

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) and Aldevron Expand Manufacturing Program to Advance Oncoprex(TM)

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced its entry into a new agreement with manufacturing partner Aldevron, LLC for expansion of Genprex’s program for the manufacture of TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA for its lead drug candidate, Oncoprex(TM) immunogene therapy. According to the update, the new agreement provides for production of TUSC2 plasmid DNA, the active agent in Oncoprex, at full commercial scale. “We are pleased with continued progress in the scale-up of our manufacturing processes,” Rodney Varner, chairman and CEO of Genprex, said in…

Continue Reading

TuesdayJun 09, 2020 10:34 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Selected to Join Russell 3000(R) Index

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it is scheduled to join the U.S. broad-market Russell 3000 Index, which includes the 3,000 publicly traded companies on the Nasdaq and NYSE exchanges with the largest market capitalizations. According to the update and a preliminary list of additions, Genprex will join the index when FTSE Russell, a leading global index provider, reconstitutes its 2020 indices after the markets close on Friday, June 26, 2020. “The selection of Genprex for the Russell 3000(R) Index will add to the awareness…

Continue Reading

TuesdayJun 09, 2020 9:45 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Financial Results for Q1 2020, Provides Business Update

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Monday reported financial results for the quarter ended March 31, 2020 and provided a business update. “We remain steadfast in our approach to assembling a portfolio of assets that leverages our unique collection of cancer tumors to develop and market AI-based, predictive models for personalized cancer treatments that improve patient outcomes,” Dr. Carl Schwartz, Predictive Oncology CEO, stated in the news release. “Our collection of more than 150,000 cancer tumors, amassed and curated over a 10-year period, gives us a…

Continue Reading

MondayJun 08, 2020 10:11 am

BioMedNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) Chairman and CEO to Present at the MoneyShow June Virtual Event

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it will present at the MoneyShow June Virtual Event at 12:50 p.m. EDT on Wednesday, June 10, 2020. According to the update, Genprex’s CEO and Chairman, Rodney Varner, will deliver a company overview and provide updates on its product pipeline, including its lead drug candidate, Oncoprex(TM) immunogene therapy, which received Fast Track Designation from the Food and Drug Administration for its combination therapy with AstraZeneca’s Tagrisso(R). He will also provide an overview of Genprex’s in-licensing of a preclinical gene…

Continue Reading

WednesdayJun 03, 2020 9:32 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Acquires Soluble Therapeutics, Inc. and BioDtech, Inc.

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, on Tuesday announced the completion of the acquisitions of two wholly owned subsidiaries of InventaBioTech, Inc., Soluble Therapeutics, Inc. and BioDtech, Inc. Included in the acquisition were certain intellectual property relating to contract research organization (“CRO”) services and technology, certain equipment useful in such services and technology and all other assets of Soluble Therapeutics and BioDtech. In consideration, POAI issued 125,000 shares of common stock and waived all remaining amounts due and payable to the company under a secured promissory note…

Continue Reading

ThursdayMay 28, 2020 12:55 pm

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Secures $2.5 Million in Cash Proceeds from Recent Warrant Exercises

Genprex (NASDAQ: GNPX) today announced the exercise of warrants to purchase approximately 5.4 million shares of common stock issued in connection with capital raises in May 2018 and November 2019 with two institutional investors at a price of $0.46 per share, resulting in its receipt of approximately $2.5 million in cash proceeds. According to the update, the warrants were exercised on or about May 22, 2020, the first day they became exercisable under their respective agreement terms. The exercised warrants represent approximately 70% of the company’s overall outstanding warrants and include all warrants that have been issued to investors in…

Continue Reading

ThursdayMay 14, 2020 11:14 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Enters Vaccine Development Race Through Acquisition, Subsequent Partnership/Licensing of Ground-Breaking Technology

Predictive Oncology (NASDAQ: POAI) has entered the race to develop a COVID19 vaccine with the announced acquisition of Soluble Therapeutics and the subsequent partnership and licensing of a novel nanoparticle vaccine technology platform recently developed by Dr. Daniel Carter. According to the update, the ground-breaking vaccine technology is based on a self-assembling nanoparticle called NSP10, which follows a foundational vaccine platform developed earlier by Dr. Carter and his team, using another self-assembling protein called ferritin*. Extremely versatile, the NSP10 Nanoparticle has special surface properties that allow for the rapid design and display of viral receptor stems for virtually any virus.…

Continue Reading

ThursdayMay 07, 2020 11:10 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces At-The-Market Priced $2.2M Registered Direct Offering

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 1,396,826 shares of its common stock. According to the update, the shares are each $1.575, in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of approximately $2.2 million. In addition, Predictive Oncology has agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 1,396,826 shares of common stock. Subject to…

Continue Reading

WednesdayMay 06, 2020 11:55 am

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Collaborates with Dr. Daniel Carter to Enter Race to Develop Potential COVID-19 Vaccine

Predictive Oncology (NASDAQ: POAI) has entered the race to develop a COVID-19 vaccine with the announced acquisition of Soluble Therapeutics, Inc. and the subsequent partnership and licensing of a novel nanoparticle vaccine platform recently developed by Dr. Daniel Carter. According to the update, the groundbreaking vaccine technology being developed by Dr. Carter is based on a self-assembling nanoparticle called NSP-10 (NSP is Non Specific Protein), which follows a foundational vaccine platform developed earlier by Dr. Carter and his team, using another self-assembling protein called ferritin (1), an iron storage protein found in all living things. NIH is currently exploiting the…

Continue Reading